Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00384 ...
Drug Name Triamterene
Molecular Weight 253.2626
Molecular Formula C12H11N7
CAS Number 396-01-0
SMILES NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1
External Links
DRUGBANK DB00384
PubChem Compound 5546
PDR 615
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 0.98 - 0.98 - HANSCH,C ET AL. (1995)
Melting Point 316.0 ℃ 316 ℃ PhysProp
Water Solubility 0.1 % <0.1 % IARC monograph, DYAZIDE hydrochlorothiazide and triamterene) Label

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
AUC 148.7 ng.h/ml 148.7 ng.h/ml Oral single dose; Male, men; fasting; DRUGBANK
Bioavailability 52.0 % 52.0 % PO, oral; DRUGBANK
Bioavailability 86.8 % 86.84 % combination drug use; DRUGBANK
Bioavailability 51.0 % 51±18 % PO, oral; The Pharmacological Basis of Therapeutics
C Max 46.4 ng/ml 46.4 ng/ml Oral single dose; Male, men; fasting; DRUGBANK
C Max 26.4 ng/ml 26.4±17.7 ng/ml Oral single dose; fasting; young; normal,healthy; The Pharmacological Basis of Therapeutics
C Max 779.0 ng/ml 779±310 ng/ml Oral single dose; Active metabolite; fasting; young; normal,healthy; The Pharmacological Basis of Therapeutics
C Max 84.0 ng/ml 84±91 ng/ml Oral single dose; Elderly; The Pharmacological Basis of Therapeutics
C Max 526.0 ng/ml 526±388 ng/ml Oral single dose; Active metabolite; Elderly; The Pharmacological Basis of Therapeutics
T Max 1.1 h 1.1 h Oral single dose; Male, men; fasting; DRUGBANK
T Max 2.9 h 2.9±1.6 h PO, oral; The Pharmacological Basis of Therapeutics
T Max 4.1 h 4.1±2.0 h PO, oral; Active metabolite; The Pharmacological Basis of Therapeutics
Clearance 270.0 L/h 4.5 L/min Plasma clearance; intravenous injection, IV; normal,healthy; DRUGBANK
Clearance 0.22 L/kg 0.22 L/kg Renal clearance; intravenous injection, IV; normal,healthy; DRUGBANK
Clearance 3.8 L/h/kg 63±20 ml/min/kg Elderly ↓ ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ; The Pharmacological Basis of Therapeutics
Clearance 3.8 L/h/kg 63 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 1.5 L/kg 1.49 L/kg intravenous injection, IV; normal,healthy; DRUGBANK
Volume of Distribution 0.11 L/kg 0.11 L/kg intravenous injection, IV; normal,healthy; DRUGBANK
Volume of Distribution 13.4 L/kg 13.4±4.9 L/kg The Pharmacological Basis of Therapeutics
Volume of Distribution 13.0 L/kg 13 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 1.8 h 1.5-2 h DRUGBANK
Half-life 4.3 h 255±42 min terminal half-life; intravenous infusion, IV in drop; normal,healthy; DRUGBANK
Half-life 3.1 h 188±70 min terminal half-life; intravenous infusion, IV in drop; normal,healthy; DRUGBANK
Half-life 4.2 h 4.2±0.7 h The Pharmacological Basis of Therapeutics
Half-life 3.1 h 3.1±1.2 h Metabolite; RD, renal impairment, Renal disease，including uremia ↑ ; The Pharmacological Basis of Therapeutics
Half-life 4.3 h 4.3 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 400.0 mg/kg 400.0 mg/kg PO, oral; Rattus, Rat; DRUGBANK
Toxicity LD50 332.5 mg/kg 285-380 mg/kg PO, oral; mouse; DRUGBANK
Eliminate Route 50.0 % <50 % Urinary excretion; PO, oral; DRUGBANK
Eliminate Route 20.0 % ~20 % Urinary excretion; PO, oral; Unchanged drug; DRUGBANK
Eliminate Route 52.0 % 52±10 % Urinary excretion; Unchanged drug; Elderly → ;Hepatic cirrhosis, cirr ↓ ; The Pharmacological Basis of Therapeutics
Protein Binding 67.0 % 67 % DRUGBANK
Protein Binding 61.0 % 61±2 % HL,hyperlipoproteinemia ↑ ;RD, renal impairment, Renal disease，including uremia ↓ ;hypoalbuminemia Alb ↓ ;Hepatic cirrhosis, cirr ↓ ; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for children 6.0 mg/kg/day 6 mg/kg/day PO, oral Dyrenium triamterene PDR
Max dose for children 300.0 mg/day 300 mg/day PO, oral Dyrenium triamterene PDR
Max dose for adolescents 300.0 mg/day 300 mg/day PO, oral Dyrenium triamterene PDR
Max dose for adults 300.0 mg/day 300 mg/day PO, oral Dyrenium triamterene PDR
Max dose for elderly 300.0 mg/day 300 mg/day PO, oral Dyrenium triamterene PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1